Micro-dosing with buprenorphine to transfer from methadone to buprenorphine – a prospective non-randomised open label clinical trial

Phase 4

Completed

• Conditions: Opioid dependence; Mental Health - Addiction

• Registration Number: ACTRN12622000444785
• Lead Sponsor: Drug Health Services, Royal Prince Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-21
• Study Completion: 2023-03-13
• Last Update Posted: 26 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

Aged greater than or equal to 18 years
-Able to provide consent and comply with the study protocol
-Prescribed a stable dose of methadone for 5 days or more for opioid dependence
-Wanting to transfer to buprenorphine

Exclusion Criteria

Pregnant
Unable to provide consent or comply with the study protocol
Contraindication to buprenorphine therapy
Allergy to buprenorphine therapy
Not currently prescribed methadone

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Success of transfer, defined as remaining on buprenorphine treatment 1 week post transfer. This will be assessed with a yes/no verbal question at a follow up appointment in person 1 week post day seven of the transfer[ 1 week post day 7 of the transfer]